Presentations & Publications Corporate Presentation May 2021 Corporate Presentation May 13, 2021 Synlogic’s Virtual R&D Event May 27, 2020 Publications Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Developing a new class of engineered live bacterial therapeutics to treat human diseases An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Presentations and Posters Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week 2020 October 22, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019 Email Alerts Contact IR RSS Feeds Print Page Email Page
Corporate Presentation May 2021 Corporate Presentation May 13, 2021 Synlogic’s Virtual R&D Event May 27, 2020 Publications Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Developing a new class of engineered live bacterial therapeutics to treat human diseases An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Presentations and Posters Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week 2020 October 22, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018)
Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates
Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021
Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021
Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020
In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020
Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week 2020 October 22, 2020
Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019
A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019
The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019
A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019